化療是腫瘤綜合治療的主要手段之一, 多藥耐藥性的產(chǎn)生是腫瘤化療中存在的主要問(wèn)題。開發(fā)多藥耐藥逆轉(zhuǎn)劑逆轉(zhuǎn)腫瘤細(xì)胞對(duì)現(xiàn)有化療藥物的耐藥性將是一種有效的治療方法。目前已有多種多藥耐藥逆轉(zhuǎn)劑處于基礎(chǔ)和臨床試驗(yàn)階段。主要從谷胱甘肽S轉(zhuǎn)移酶、蛋白激酶C、凋亡通路受阻、拓?fù)洚悩?gòu)酶和DNA修復(fù)能力增強(qiáng)等方面介紹非經(jīng)典的多藥耐藥逆轉(zhuǎn)劑。

Chemotherapy plays an essential role in the combined therapy of tumor, while the emergence of multidrug resistance in tumor cells can always lead the therapy to failure. The development of multidrug resistance reversal agents is a promising approach to overcome the resistance of current chemotherapeutic agents. Presently, various kinds of reversal agents have already been in basic and clinical study. The research progress of atypical multidrug resistance reversal agents are summarized from glutathione S-transferases, protein kinase C, block of apoptotic pathways, topoisomerase, and enhancement of DNA repair in this brief review.